309 related articles for article (PubMed ID: 30186764)
1. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species.
Oliveira F; Leuzy A; Castelhano J; Chiotis K; Hasselbalch SG; Rinne J; Mendonça A; Otto M; Lleó A; Santana I; Johansson J; Anderl-Straub S; Arnim C; Beer A; Blesa R; Fortea J; Sanna-Kaisa H; Portelius E; Pannee J; Zetterberg H; Blennow K; Moreira AP; Abrunhosa A; Nordberg A; Castelo-Branco M
Neuroimage Clin; 2018; 20():603-610. PubMed ID: 30186764
[TBL] [Abstract][Full Text] [Related]
2. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.
Weigand SD; Vemuri P; Wiste HJ; Senjem ML; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS; Jack CR;
Alzheimers Dement; 2011 Mar; 7(2):133-41. PubMed ID: 21282074
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
[TBL] [Abstract][Full Text] [Related]
5. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
Grimmer T; Riemenschneider M; Förstl H; Henriksen G; Klunk WE; Mathis CA; Shiga T; Wester HJ; Kurz A; Drzezga A
Biol Psychiatry; 2009 Jun; 65(11):927-34. PubMed ID: 19268916
[TBL] [Abstract][Full Text] [Related]
6. Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.
Korecka M; Figurski MJ; Landau SM; Brylska M; Alexander J; Blennow K; Zetterberg H; Jagust WJ; Trojanowski JQ; Shaw LM;
Clin Chem; 2020 Apr; 66(4):587-597. PubMed ID: 32087019
[TBL] [Abstract][Full Text] [Related]
7. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
[TBL] [Abstract][Full Text] [Related]
8. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
9. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
10. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W
J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
12. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Zhang S; Smailagic N; Hyde C; Noel-Storr AH; Takwoingi Y; McShane R; Feng J
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010386. PubMed ID: 25052054
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease.
Adamczuk K; Schaeverbeke J; Vanderstichele HM; Lilja J; Nelissen N; Van Laere K; Dupont P; Hilven K; Poesen K; Vandenberghe R
Alzheimers Res Ther; 2015 Dec; 7(1):75. PubMed ID: 26677842
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
15. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
[TBL] [Abstract][Full Text] [Related]
16. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
19. White Matter Reference Region in PET Studies of
Lowe VJ; Lundt ES; Senjem ML; Schwarz CG; Min HK; Przybelski SA; Kantarci K; Knopman D; Petersen RC; Jack CR
J Nucl Med; 2018 Oct; 59(10):1583-1589. PubMed ID: 29674420
[TBL] [Abstract][Full Text] [Related]
20. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
